Myriad Announces Publication of Vectra® Study in Journal Rheumatology
December 26 2018 - 7:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in
personalized medicine, today announced the results from a large
commercial cohort and several clinical studies on development of
the adjusted Vectra
® score that were published in
the journal Rheumatology. The key findings are that the
adjusted Vectra score significantly outperformed conventional
measures of disease activity in predicting radiographic progression
(new joint damage) in patients with rheumatoid arthritis (RA).
“This study showed that the adjusted Vectra score
was the strongest individual predictor of new radiographic joint
damage over one year in patients with RA,” said Jerry Lanchbury,
Ph.D., chief scientific officer, Myriad Genetics. “In these
analyses, the adjusted Vectra score was three times more predictive
of radiographic joint damage than DAS28-CRP and five times more
predictive than DAS28* and was significantly better than other
disease activity measures commonly used by clinicians today.”
This large study included a cohort of more than
300,000 commercially tested patients with RA and 1,411 RA patients
from a clinical trial/registry cohort. An adjusted Vectra DA
score was developed to account for three factors known to impact
inflammation: age, gender, and degree of adiposity proxied either
by serum leptin level or body mass index (BMI). In addition,
the adjusted Vectra scores were evaluated for their ability to
predict radiographic progression (RP) and compared with other
disease activity measures, including DAS28, DAS28-CRP, SDAI, and
CDAI. The results showed that the leptin-adjusted Vectra score
was 5.5 times more predictive of radiographic progression, the
BMI-adjusted Vectra score was 4.6 times more predictive, and the
original Vectra score was four times more predictive when compared
to DAS28. Importantly, Vectra also outperformed the other
common measures evaluated in this study (Chart 1).
A chart accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/19e6ca49-b384-4056-848e-66bca3e7ed1d
“The Vectra test allows one to identify patients with a high
degree of inflammatory activity, which can lead to join damage
progression,” said Elena Hitraya, M.D., Ph.D., chief medical
officer, Myriad Autoimmune. “This study showed that the
adjusted Vectra score significantly improved ability to predict
radiographic progression and thus, it provides valuable information
to clinicians that they can incorporate into the individual patient
treatment plans”.
About Rheumatoid ArthritisRheumatoid arthritis
is an autoimmune disease that mainly attacks the body’s joints,
leading to significant morbidity and financial burden.
Approximately 60 percent of people with inadequately treated RA are
unable to work 10 years after onset. The American College of
Rheumatology estimates that RA affects 1.3 million people in the
United States.
About Vectra Vectra is a multi-biomarker
molecular blood test that provides an objective and personalized
measure of inflammatory disease activity in patients with
rheumatoid arthritis. Vectra demonstrates unsurpassed ability to
predict radiographic progression and guides medical management
decisions to improve patient outcomes. Vectra testing is
performed at a state-of-the-art CLIA (Clinical Laboratory
Improvement Amendments) facility. Test results are reported to the
physician five to seven days from shipping of the specimen.
Physicians can receive test results by fax or the private web
portal, VectraView. For more information on Vectra, please visit:
www.vectrada.com.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: build upon a solid hereditary
cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP,
myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice,
myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD,
EndoPredict, Vectra, GeneSight, riskScore Prolaris, ForeSight and
Prelude are trademarks or registered trademarks of Myriad Genetics,
Inc. or its wholly owned subsidiaries in the United States and
foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements related to results of the study published in the journal
Rheumatology; the adjusted Vectra score significantly outperforming
conventional measures of disease activity in predicting
radiographic progression (new joint damage) in patients with
rheumatoid arthritis; the adjusted Vectra score being three times
more predictive of radiographic joint damage than DAS28-CRP and
five times more predictive than DAS28* and significantly better
than other disease activity measures commonly used by clinicians
today; the adjusted Vectra score being the strongest individual
predictor of new radiographic joint damage over one year in
patients with RA; the Vectra test allowing one to identify patients
with a high degree of inflammatory activity, which can lead to join
damage progression; the adjusted Vectra score significantly
improved ability to predict radiographic progression and providing
valuable information to clinicians that they can incorporate into
the individual patient treatment plans; the Company’s ongoing
commitment to proving rheumatologists with valuable information
about a patient’s disease activity that can help direct treatment
strategies and improve patient outcomes; and the Company's
strategic directives under the caption "About Myriad
Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers’
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; the risk that
we may be unable to comply with financial operating covenants under
our credit or lending agreements; the risk that we will be
unable to pay, when due, amounts due under our credit or lending
agreements; and other factors discussed under the heading "Risk
Factors" contained in Item 1A of our most recent Annual Report on
Form 10-K for the fiscal year ended June 30, 2018, which has been
filed with the Securities and Exchange Commission, as well as any
updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. All information in this press release is as of the date
of the release, and Myriad undertakes no duty to update this
information unless required by law.
Media Contact: Ron Rogers
801) 584-3065
rrogers@myriad.com
Investor Contact:Scott Gleason (801)
584-1143sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024